Currently, the most common medication for CPP is leuprorelin, which is a gonadotropin-releasing hormone (GnRH) analog, and the use of leuprorelin for suppressing puberty patients with CPP caused by MKRN3 mutations has been reported. Here, MKRN3 is linked to central precocious puberty.